Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Hepatic Fibrosis in Patients With Type 2 Diabetes: A Chart-Based Analysis

Hisayuki Katsuyama, Mariko Hakoshima, Takehiro Iijima, Hiroki Adachi, Hidekatsu Yanai

Abstract


Background: The presence of nonalcoholic fatty liver diseases (NAFLDs) and type 2 diabetes was associated with elevated risks of cardiovascular events as well as the progression of NAFLD to fibrosis/cirrhosis and hepatocellular carcinoma. Sodium-glucose cotransporter 2 inhibitor (SGLT2i) is a widely used antidiabetic drug, which promotes urinary excretion of glucose. Recent animal and human studies demonstrated the beneficial effects of SGLT2is on lipid accumulation and fibrosis in the liver. The purpose of the current study was to elucidate the effects of SGLT2is on hepatic fibrosis in the real-world setting.

Methods: We selected patients with type 2 diabetes who had been prescribed SGLT2is continuously for 12 months between April 1, 2014 and March 31, 2018 by a chart-based analysis. We compared the data before the SGLT2is treatment with the data at 6 and 12 months after the SGLT2is treatment started. Fibrosis in the liver was evaluated by fibrosis-4 (FIB4) index.

Results: We enrolled 315 patients in this study. The body weight, body mass index (BMI), serum levels of aspartate aminotransferase, alanine aminotransferase and gamma-glutamyl transferase were significantly decreased at 6 months and maintained at 12 months, whereas there was no significant change in FIB4 index. We divided the studied patients into three groups according to the baseline FIB4 index. Only in the group of high value of the baseline FIB4 index, FIB4 index was significantly decreased at 12 months. The correlations between the change of FIB4 index during 12-month SGLT2i treatment was correlated inversely with the baseline FIB4 index.

Conclusion: Present study demonstrated that SGLT2i could ameliorate fibrosis in the liver in high-risk patients for hepatic fibrosis.




J Endocrinol Metab. 2020;10(1):1-7
doi: https://doi.org/10.14740/jem632


Keywords


Hepatic fibrosis; Nonalcoholic fatty liver diseases; Sodium-glucose cotransporter 2 inhibitor

Full Text: HTML PDF
 

Browse  Journals  

 

Journal of Clinical Medicine Research

Journal of Endocrinology and Metabolism

Journal of Clinical Gynecology and Obstetrics

 

World Journal of Oncology

Gastroenterology Research

Journal of Hematology

 

Journal of Medical Cases

Journal of Current Surgery

Clinical Infection and Immunity

 

Cardiology Research

World Journal of Nephrology and Urology

Cellular and Molecular Medicine Research

 

Journal of Neurology Research

International Journal of Clinical Pediatrics

 

 
       
 

Journal of Endocrinology and Metabolism, bimonthly, ISSN 1923-2861 (print), 1923-287X (online), published by Elmer Press Inc.                     
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)


This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.jofem.org   editorial contact: editor@jofem.org    elmer.editorial2@hotmail.com
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.


Disclaimer: The views and opinions expressed in the published articles are those of the authors and do not necessarily reflect the views or opinions of the editors and Elmer Press Inc. This website is provided for medical research and informational purposes only and does not constitute any medical advice or professional services. The information provided in this journal should not be used for diagnosis and treatment, those seeking medical advice should always consult with a licensed physician.